/
EW
$90.19-$1.00 (-1.09%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$52.3B
576M shares
52-week range
$72.30 – $92.88
87% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-14.63
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.72B | $4.35B | $4.39B | $5.23B | $5.38B | $5.01B | $5.44B | $6.07B |
| Cost of revenue | $922.1M | $1.16B | $1.10B | $1.23B | $1.17B | $1.04B | $1.12B | $1.33B |
| Gross profit | $2.80B | $3.19B | $3.29B | $4.01B | $4.22B | $3.97B | $4.32B | $4.74B |
| Gross margin | 75.2% | 73.4% | 74.9% | 76.6% | 78.3% | 79.3% | 79.5% | 78.1% |
| R&D | $622.2M | $752.7M | $760.7M | $903.1M | $945.2M | $962.9M | $1.05B | $1.08B |
| Operating income | $1.09B | $1.20B | $1.30B | $1.61B | $1.70B | $1.43B | $1.38B | $1.64B |
| EBITDA | $872.2M | $1.31B | $1.07B | $1.89B | $1.96B | $1.53B | $1.72B | $1.43B |
| Net income | $722.2M | $1.05B | $823.4M | $1.50B | $1.52B | $1.40B | $4.17B | $1.07B |
| Net margin | 19.4% | 24.1% | 18.8% | 28.7% | 28.3% | 28.0% | 76.7% | 17.7% |
| EPS (diluted) | 1.13 | 1.64 | 1.30 | 2.38 | 2.44 | 2.30 | 6.97 | 1.83 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6.8B | $3.01 | $2.97–$3.03 | 16 |
| 2027 | $7.4B | $3.38 | $3.32–$3.50 | 16 |
| 2028 | $8.2B | $3.80 | $3.70–$3.90 | 7 |
| 2029 | $9.0B | $4.24 | $4.09–$4.32 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$63.86
Price
$90.19
Implied downside
-29%
Peer comparison
Edwards Lifesciences Corp
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
www.edwards.com- Employees
- 16,000
- IPO / List date
- Apr 3, 2000
- HQ
- IRVINE, CA
Held by traders on TradeandTell
No one on the platform currently holds EW.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 171,923 | $13.8M |
| Renaissance Technologiesas of 2026-03-31 | 29,000 | $2.3M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2020-06-01 | 3-for-1 |
| 2015-12-14 | 2-for-1 |
| 2010-05-28 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded EW yet.
